Review



fgfr-specific small-molecule inhibitors  (Janssen)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Janssen fgfr-specific small-molecule inhibitors
    Fgfr Specific Small Molecule Inhibitors, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fgfr-specific+small-molecule+inhibitors/atp+competitive+small+molecule+tyrosine+kinase+inhibitor+against+fgfr1+4+jnj+42756493/10__1172_slash_jci174171-29-8-43
    Average 90 stars, based on 1 article reviews
    fgfr-specific small-molecule inhibitors - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Expressing:

    Article Title: Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer
    Article Snippet: In recent years, the FDA has approved various FGFR-specific small-molecule inhibitors via their Accelerated Approval Program for the treatment of metastatic urothelial bladder carcinoma (erdafitinib [JNJ-42756493], objective response rate Related Article: https://doi.org/10.1172/JCI170217 Conflict of interest: MM receives research support from Bayer, Ono, and Janssen; patent licensing royalties from Bayer (patents including US patent no. 11,427,553, “Dihydrooxadiazinones”; US patent no. 11,339,157, “4H-pyrrolo[3,2-c]pyridin-4-one derivatives”; US patent no. 11,207,320, “Compositions and methods for cancer expressing PDE3A or SLFN12”; US patent no. 11,142,522, “Compounds, compositions and methods for cancer treatment”; US patent no. 10,966,986, “Compounds, compositions and methods for cancer patient stratification and cancer treatment”; and US patent no. 9,890,127, “Compounds and compositions for the treatment of cancer,” as well as patents pending) and LabCorp (US patent nos.

    Clinical Proteomics:

    Article Title: Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer
    Article Snippet: In recent years, the FDA has approved various FGFR-specific small-molecule inhibitors via their Accelerated Approval Program for the treatment of metastatic urothelial bladder carcinoma (erdafitinib [JNJ-42756493], objective response rate Related Article: https://doi.org/10.1172/JCI170217 Conflict of interest: MM receives research support from Bayer, Ono, and Janssen; patent licensing royalties from Bayer (patents including US patent no. 11,427,553, “Dihydrooxadiazinones”; US patent no. 11,339,157, “4H-pyrrolo[3,2-c]pyridin-4-one derivatives”; US patent no. 11,207,320, “Compositions and methods for cancer expressing PDE3A or SLFN12”; US patent no. 11,142,522, “Compounds, compositions and methods for cancer treatment”; US patent no. 10,966,986, “Compounds, compositions and methods for cancer patient stratification and cancer treatment”; and US patent no. 9,890,127, “Compounds and compositions for the treatment of cancer,” as well as patents pending) and LabCorp (US patent nos.



    Similar Products

    fgfr-specific small-molecule inhibitors  (Janssen)
    90
    Janssen fgfr-specific small-molecule inhibitors
    Fgfr Specific Small Molecule Inhibitors, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fgfr-specific+small-molecule+inhibitors/atp+competitive+small+molecule+tyrosine+kinase+inhibitor+against+fgfr1+4+jnj+42756493/10__1172_slash_jci174171-29-8-43
    Average 90 stars, based on 1 article reviews
    fgfr-specific small-molecule inhibitors - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results